Use of genome-wide DNA methylation analysis to identify prognostic CpG site markers associated with longer survival time in dogs with multicentric high-grade B-cell lymphoma.
Teoh YB, Ishizaki T, Kagawa Y, Yokoyama S, Jelinek J, Matsumoto Y, Tomiyasu H, Tsujimoto H, Takiguchi M, Yamazaki J · Journal of Veterinary Internal Medicine · 19 December 2024
DNA methylation analysis may predict survival in dogs with MHGL.
This study investigated the potential of genome-wide DNA methylation analysis to identify prognostic CpG sites associated with longer survival times in dogs with multicentric high-grade B-cell lymphoma (MHGL) treated with CHOP chemotherapy. The researchers performed DNA methylation profiling on tumor samples from 20 dogs diagnosed with MHGL. They identified specific CpG sites whose methylation status correlated with survival outcomes. The findings suggest that DNA methylation patterns could serve as prognostic biomarkers, aiding in predicting survival times and potentially guiding therapeutic decisions. However, the study emphasizes the need for further validation in larger cohorts to confirm these findings and assess their clinical applicability.
This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.